Study Summary
This is a single-center, open-label study to evaluate the safety and efficacy of A-CAR028 in relapsed/refractory acute myeloid leukemia patients
Want to learn more about this trial?
Request More InfoInterventions
A-CAR028BIOLOGICAL
A-CAR028 is a novel 2nd generation 4-1BB bispecific chimeric antigen receptor T-cell (CAR-T) targeting both CD33 and CLL-1 antigens
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University | Hangzhou | Zhejiang | China |